Lantheus Omega and related Lantheus entities are reported as beneficial owners of 20.9% of Radiopharm Theranostics’ ordinary shares, based on holdings and options. The position matters to investors because it combines issued stock with Options to purchase 255,000,000 additional shares at AUD $0.039 each, expiring on October 31, 2027.
Key Highlights
- Lantheus Omega’s position includes 255,000,000 ordinary shares issued on December 9, 2025.
- Options covering 255,000,000 ordinary shares carry an AUD $0.039 exercise price and expire on October 31, 2027.
- The ownership percentage is calculated using 3,544,216,160 ordinary shares outstanding as of June 30, 2026, plus the option shares.
Radiopharm Theranostics Ltd (NASDAQ: RADX) has a reported beneficial ownership position of 20.9% linked to Lantheus Omega, Lantheus Medical Imaging and Lantheus Holdings (NASDAQ: LNTH). The percentage represents the aggregate position as of July 27, 2026, including ordinary shares and options tied to the December issuance.
Lantheus Position Includes Shares and Options
Lantheus Omega holds 149,625,180 Radiopharm ordinary shares issued on August 23, 2024, along with 133,333,333 shares issued on January 20, 2025. The entity also received 255,000,000 ordinary shares on December 9, 2025. The reporting entities said they had no current plans or proposals relating to specified corporate actions. They may review or change that position, or develop such plans, at any time.
FAQs
Q: What is Lantheus Omega’s stake in Radiopharm Theranostics?
A: Lantheus Omega and related Lantheus entities are reported to beneficially own 20.9% of Radiopharm Theranostics’ ordinary shares, including securities held through Lantheus Omega.
Q: How many Radiopharm shares can Lantheus buy through options?
A: The options allow Lantheus Omega to purchase 255,000,000 Radiopharm ordinary shares at AUD $0.039 per share. They expire on October 31, 2027.
Q: What does the Radiopharm ownership percentage include?
A: The 20.9% beneficial ownership figure includes issued ordinary shares and the 255,000,000 shares issuable upon option conversion. The calculation uses 3,544,216,160 shares outstanding as of June 30, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.